
The RECOVERY Trial: Tocilizumab
…immunomodulatory agents may provide additional patient-oriented improvements. Enter Tocilizumab. This is a recombinant anti-IL6 receptor monoclonal antibody that inhibits binding of IL-6 to receptors that signal inflammation. The results of…



